State TN
Clinical Trials in Tennessee
Tennessee is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Tennessee and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 312 actively recruiting studies with Tennessee sites out of 312 registered in total. The busiest research areas in Tennessee are Breast Cancer, Endometrial Cancer, Advanced Solid Tumors. Leading sponsors running trials in the state include Vanderbilt University Medical Center, St. Jude Children's Research Hospital, AstraZeneca. By stage, Tennessee trials break down as Phase 1 (80), Phase 2 (93), Phase 3 (93), Phase 4 (12).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Tennessee
Frequently Asked Questions — Clinical Trials in Tennessee
How many clinical trials are currently recruiting in Tennessee?
ClinicalMetric currently tracks 312 actively recruiting clinical trials with at least one location in Tennessee. The total number of registered studies—including active but not currently enrolling trials—is 312. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Tennessee?
Tennessee hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Endometrial Cancer, Advanced Solid Tumors, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Tennessee serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Tennessee?
To join a clinical trial in Tennessee, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Tennessee maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Tennessee
NCT07686081 Phase 3
Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients Wit...
Condition
Ulcerative Colitis (UC)
Enrollment
150 pts
Location
United States
Sponsor
Vanda Pharmaceuticals
NCT06581328 Phase 4
Recruiting
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in t...
Condition
Ulcerative Colitis
Enrollment
400 pts
Location
United States
Sponsor
Takeda
NCT03378557 N/A
Recruiting
Periprosthetic Fracture Registry (PPFx)
Condition
Periprosthetic Fractures
Enrollment
600 pts
Location
United States, Belgium, Colombia
Sponsor
AO Innovation Translation Cent
NCT05659381 Phase 3
Recruiting
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary P...
Condition
Stage III Ovarian Cancer
Enrollment
220 pts
Location
United States
Sponsor
GOG Foundation
NCT04671212 N/A
Recruiting
Discarded Bone Marrow for Hematology Research
Condition
Hemoglobinopathies
Enrollment
50 pts
Location
United States
Sponsor
St. Jude Children's Research H
NCT04172532 Phase 1, Phase 2
Recruiting
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual...
Condition
Locally Advanced Pancreatic Adenocarcinoma
Enrollment
92 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07531498 N/A
Recruiting
Muscle Aging Phenotypes in Childhood Cancer Survivors
Condition
Muscle Weakness
Enrollment
533 pts
Location
United States
Sponsor
St. Jude Children's Research H
NCT05034432 Phase 4
Recruiting
The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventri...
Condition
Arrythmia
Enrollment
100 pts
Location
United States
Sponsor
University of Rochester
NCT06307665 Phase 3
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As ...
Condition
Asthma
Enrollment
440 pts
Location
United States, China, Mexico
Sponsor
AstraZeneca
NCT05877599 Phase 1
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Posi...
Condition
Non-small Cell Lung Cancer
Enrollment
45 pts
Location
United States
Sponsor
AstraZeneca
NCT04871542 N/A
Recruiting
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Condition
Malignant Solid Neoplasm
Enrollment
2,062 pts
Location
United States, Chile, Guam
Sponsor
SWOG Cancer Research Network
NCT06521372 N/A
Recruiting
The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using ...
Condition
Infertility Primary
Enrollment
450 pts
Location
United States
Sponsor
Ovation Fertility
NCT05232916 Phase 3
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (...
Condition
Breast Cancer
Enrollment
2,250 pts
Location
United States, Belgium, France
Sponsor
Greenwich LifeSciences, Inc.
NCT07747103 Phase 3
Recruiting
An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North ...
Condition
Hypothyroidism
Enrollment
466 pts
Location
United States
Sponsor
Neuvosyn Laboratories, LLC
NCT07409207 N/A
Recruiting
Neurophysiology of Reward Signaling in Parkinson's Disease
Condition
Parkinson Disease
Enrollment
75 pts
Location
United States
Sponsor
Vanderbilt University Medical
NCT07165132 Phase 1
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Condition
GEP-NET
Enrollment
104 pts
Location
United States, Canada
Sponsor
RayzeBio, Inc.
NCT07207993 N/A
Recruiting
Evaluating Health Outcomes of AI-Based Fitness Wearables and App Programs in Old...
Condition
Older Adults With Cognitive Decline
Enrollment
64 pts
Location
United States
Sponsor
The University of Tennessee, K
NCT06311214 Phase 2
Recruiting
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing fo...
Condition
Advanced Malignant Solid Neoplasm
Enrollment
500 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07405164 Phase 3
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043...
Condition
Von Hippel-Lindau Disease
Enrollment
450 pts
Location
United States, Australia, Belgium
Sponsor
Merck Sharp & Dohme LLC
NCT07326709 Phase 3
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Part...
Condition
Huntington Disease
Enrollment
770 pts
Location
United States, Argentina, Australia
Sponsor
Novartis Pharmaceuticals
NCT07016399 Phase 2
Recruiting
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
51 pts
Location
United States
Sponsor
Vandana Abramson
NCT05966493 Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic G...
Condition
Persistent Corneal Epithelial Defect
Enrollment
84 pts
Location
United States, Germany, Italy
Sponsor
Glaukos Corporation
NCT05006716 Phase 1, Phase 2
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participant...
Condition
B-cell Malignancy
Enrollment
645 pts
Location
United States, Australia, Brazil
Sponsor
BeOne Medicines
NCT07497087 Phase 3
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Condition
Systemic Sclerosis
Enrollment
448 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT02523014 Phase 2
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating ...
Condition
Intracranial Meningioma
Enrollment
124 pts
Location
United States
Sponsor
Alliance for Clinical Trials i
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology